CFI-402257

DRUG4 trials

Sponsors

University Health Network, Toronto, Canadian Cancer Trials Group, Treadwell Therapeutics, Inc

Conditions

Advanced Solid CancersAdvanced Solid TumorBreast Cancer

Phase 1

A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors

Active, not recruitingNCT02792465

University Health Network, TorontoAdvanced Solid Cancers, Breast Cancer

Start: 2016-11-11End: 2027-05-31Target: 52Updated: 2024-01-17

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Active, not recruitingNCT03568422

Canadian Cancer Trials GroupBreast Cancer

Start: 2019-02-05End: 2026-12-31Updated: 2026-03-27

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

Active, not recruitingNCT05251714

Treadwell Therapeutics, IncAdvanced Solid Tumor, Breast Cancer

Start: 2022-05-27End: 2026-08-31Target: 44Updated: 2025-05-18

Phase 2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

RecruitingNCT05601440

Canadian Cancer Trials GroupBreast Cancer

Start: 2023-06-13End: 2028-06-30Target: 484Updated: 2026-03-27

Related Papers

IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast.

Journal of Clinical Oncology2025-05-281 citations

Abstract PO2-04-13: TWT-203: PHASE 1b/2 STUDY OF CFI-402257 AS MONOTHERAPY IN ADVANCED SOLID TUMORS AND IN COMBINATION WITH FULVESTRANT IN PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER AFTER PROGRESSION ON PRIOR CDK4/6 INHIBITORS AND ENDOCRINE THERAPY

Cancer Research2024-05-021 citations

Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).

Journal of Clinical Oncology2019-05-201 citations

Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).

Journal of Clinical Oncology2019-03-013 citations

Phase I study of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors.

Journal of Clinical Oncology2017-05-204 citations